Human Stem Cells Institute (HSCI) will invest RUB 45 million in its subsidiary Betuvax LLC in order to develop and adopt new coronavirus vaccines, the institute informed.
The Board of Directors of HSCI approved an investment loan agreement with Betuvax which will use the investment to develop and promote the adoption of coronavirus vaccines. The money will be used to complete preclinical studies, to produce vaccine series for the launch of clinical trials, and to develop a generation of candidate vaccines, including those to treat new coronavirus strains.
The Human Stem Cells Institute is a biotechnology holding company managing companies and projects related to biotechnology and healthcare. The HSCI team is committed to implementing new methods of treatment related to regenerative medicine, gene therapy, tissue engineering, genetic testing, and reproductive medicine in the Russian healthcare practice.
